PHASE-II STUDY - ADJUVANT SINGLE-AGENT CARBOPLATIN THERAPY FOR CLINICAL STAGE-I SEMINOMA

Objective: Though para-aortal and ipsilateral iliacal radiation is the established adjuvant treatment for clinical stage I seminoma, promisi ng results have been reported on adjuvant single-agent carboplatin the rapy. Patients and Methods: We treated 43 patients with clinical stage I seminoma according to this option. They received 2 courses of singl e-agent carboplatin (400 mg/m(2)) at an intervall of 3 weeks. Therapy could be performed on an outpatient basis within 2 h. Results: Therapy was well tolerated. Apart from minor gastrointestinal disorders and m ild myelosuppression, no adverse reactions were observed. The median f ollow-up is 28 months. Up to now no recurrences have been noted. Concl usions: If the recurrence rate remains as low as after adjuvant radiot herapy, which should be proved in a phase III study, single-agent carb oplatin therapy will be an alternative adjuvant approach for clinical stage I seminoma.